tbResList Print — Tras Trastuzumab

Filters: qv=260, qv2=%, rfv=%

Product

Tras Trastuzumab
Description: <b>Trastuzumab</b> is a targeted therapy used in the treatment of certain types of cancer, most notably HER2-positive breast cancer. <br>
<br>
It specifically targets the human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in some types of breast cancer and other cancers.<br>
-Is a Her2 inhibitor used in breast cancer. <br>
<br>
Trastuzumab has revolutionized the treatment of HER2-positive breast cancer, significantly improving both response rates and overall survival.<br>

Pathway results for Effect on Cancer / Diseased Cells

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp8↑, 1,   p‑p38↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Autophagy & Lysosomes ⓘ

p62↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   mTOR↓, 1,   PI3K↓, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

HER2/EBBR2↓, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2025ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLSR. Serttas—https://exp-oncology.com.ua/index.php/Exp/article/view/4960
2017Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cellsCarolina D’AlesioPMC5670707https://pmc.ncbi.nlm.nih.gov/articles/PMC5670707/0